Press Releases 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 Eagle Pharmaceuticals Announces Worldwide Licensing Agreement with Combioxin SA for Phase 2b/3, Novel First-in-Class Antitoxin Agent CAL02 in Development for Combination Use with Antibiotics for the Treatment of Severe Pneumonia 8/25/21 Eagle Pharmaceuticals Reports Second Quarter 2021 Results 8/9/21 Eagle Pharmaceuticals Announces Licensing Agreement with AOP Orphan for U.S. Commercial Rights to Landiolol, a Beta-1 Adrenergic Blocker 8/9/21 Eagle Pharmaceuticals to Host Second Quarter 2021 Financial Results on August 9, 2021 7/28/21 Eagle Pharmaceuticals Announces FDA Maintains Prioritization of ANDA for Vasopressin 6/24/21 Eagle Pharmaceuticals Submits Response to Complete Response Letter from FDA for Vasopressin 6/17/21 Eagle Pharmaceuticals to Present at Jefferies Virtual Healthcare Conference 2021 5/26/21 Eagle Pharmaceuticals to Present at the 2021 RBC Capital Markets Global Healthcare Conference 5/11/21 Eagle Pharmaceuticals Reports First Quarter 2021 Results 5/10/21 Eagle Pharmaceuticals Announces Filing of TREAKISYM (bendamustine) Rapid Infusion (“RI”) Liquid Formulation in Japan 5/10/21 Pagination First page Previous page Page 1 Current page 2 Page 3 Next page Last page
